Lemtrada decision expected in Q4; Discovery Labs nabs $30M loan;

 @FierceBiotech: Sanofi rebuilds early-stage R&D strategy in thriving Boston/Cambridge hub. Story | Follow @FierceBiotech

@JohnCFierce: Gregoire exits Shire HGT one step ahead of new CEO's debut (any chance this is connected to new CEO selection?) Article | Follow @JohnCFierce

@RyanMFierce: Boehringer Ingelheim goes to Hungary for R&D software. Article | Follow @RyanMFierce

> Genzyme CEO David Meeker told an industry group today that he is expecting an FDA decision on the multiple sclerosis treatment Lemtrada in the fourth quarter of 2013. Story

> Discovery Laboratories ($DSCO) says it's lined up a $30 million loan from Deerfield Management. Story

> Citing a downturn in the industry, Huntingdon Life Sciences in the U.K. let go of 95 staffers. Story

> The U.K.'s Domainex has lined up $2.3 million in new venture funding. Story

Pharma News

@FiercePharma: Pharma girds for battle against Medicaid-level rebates for 'dual eligibles.' Fought and won before, but this time? More | Follow @FiercePharma

@EricPFierce: Takeda and one of its contract manufacturers sanctioned by Japanese regulator. Plant ordered closed for 12 days. News | Follow @EricPFierce

@AlisonBFierce: 2012 marked the largest whooping cough outbreak in 50 years. A new vaccine-resistant strain may be to blame. Report | Follow @AlisonBFierce

> Eylea boosts Regeneron past estimates; Actelion hikes dividend for waiting investors. Story

> Merck to pay $688M in lawsuit over failed Vytorin study. Article

> Teva's at-risk Protonix launch could cost $2B-plus. News

Medical Device News

 @FierceMedDev: Special Report: R&D advances in cancer Dx. Special Report | Follow @FierceMedDev

 @MarkHFierce: Medtronic wins with new study that touts merit of DBS for early Parkinson's. More | Follow @MarkHFierce

 @DamianFierce: The medical device tax is particularly treacherous for small companies, Theragenics says. Article | Follow @DamianFierce

> Rigid FX cited for quality violations concerning orthopedic surgical device. Item

> Hospira back in FDA's sights over device manufacturing. Story

Pharma Manufacturing News

> Takeda, CMO hit with sanctions by Japanese regulator. More

> Baxter beefing up cytotoxic manufacturing. Story

> Sanofi again turns to Waterford plant for production solution. Report

> Hospira moves forward with two plants in India. Article

Vaccines News

> Study: Untreated depression decreased effectiveness of shingles vaccine. More

> New whooping cough strain may resist vaccine. Story

> PharmaJet needle-free injector nabs WHO nod. Article

> EMA: Intercell can market Ixiaro in EU. More

> GSK flu vaccine additive under the microscope. Report

And Finally… Officials say an 11th person has been infected with a SARS-like virus, arousing concerns about a potential outbreak. Story

 

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.